Last Week in Cannabis #10
October 5–11, 2026 | Issue #10
Hey friend — welcome back to Last Week in Cannabis. The DEA made an official confirmation this week that made headlines, the Massachusetts cannabis vote is heating up, and the UK’s medical cannabis market keeps growing. Let’s get into it.
1. UNITED STATES — The DEA Formally Confirmed There Are No Known Cannabis Overdose Deaths
An updated report published by the DEA this week formally stated that there are no known instances of someone fatally overdosing from consuming cannabis. The confirmation came as the agency continues its ongoing rescheduling process, during which its own witnesses testified to cannabis’s medical value and relative safety compared to alcohol and opioids.
Mary Jane’s Take: This is a significant moment to have on the official record. The DEA — the agency responsible for enforcing cannabis prohibition — has now formally confirmed that cannabis has no known fatal overdose cases. Cannabis is currently classified in the same Schedule I category as heroin, which is defined as having no accepted medical use and a high potential for abuse. The gap between that classification and the scientific and epidemiological reality keeps widening. A substance with no recorded fatal overdose, medical uses documented in 17 countries, and consumption by more than one in five American adults has a hard time fitting in the same category as the drugs responsible for a hundred thousand American deaths a year.
2. UNITED STATES — The Massachusetts Cannabis Repeal Vote Is Heating Up — and Senators Are Weighing In
With the November 3rd vote on Question 8 — the ballot measure that would repeal Massachusetts’s adult-use cannabis laws — drawing closer, the campaign is intensifying. Governor Maura Healey publicly urged voters this week to reject the repeal, saying she hopes voters keep cannabis. A group of US senators also came out against the repeal initiative. Meanwhile, the pro-repeal campaign launched new ads focused on impaired driving concerns.
Current polling continues to show roughly 55% of voters opposed to the repeal, with around 33% in favour and the remainder undecided.
Mary Jane’s Take: The fact that a sitting governor and multiple US senators are actively campaigning against a cannabis repeal initiative tells you something about how far the political conversation has moved. Ten years ago, elected officials in either party rarely went on record in favour of cannabis legalization. Now they are campaigning to protect it. The ads focused on impaired driving are the repeal campaign’s strongest argument — it resonates with parents and safety-conscious voters who might otherwise lean toward keeping legalization. Whether the 55-33 polling gap holds through to November 3rd remains to be seen. Three weeks to go.
3. UNITED KINGDOM — More British Women Are Turning to Medical Cannabis for Chronic Pain
The Independent reported this week that growing numbers of British women with chronic pain are turning to medical cannabis after conventional treatments — including over-the-counter medications — have failed to provide adequate relief. The Medical Cannabis Clinicians Society estimates approximately 80,000 people are currently using medical cannabis in the UK, and that number continues to grow.
Mary Jane’s Take: Chronic pain is one of the most common and most undertreated conditions in modern medicine, and women are disproportionately affected by conditions like fibromyalgia, endometriosis, and arthritis that can cause persistent, severe pain with limited conventional treatment options. The UK’s medical cannabis programme has been operating since 2018, and the patient base is growing steadily as more people and more physicians become comfortable with it. The story of women seeking cannabis when conventional medicine has not helped them is not unique to the UK — it is one of the most consistent themes across every medical cannabis market in the world.
4. GLOBAL — A Global Regulatory Summit Just Published a Blueprint for Aligning Cannabis Rules Across Countries
The Global Cannabis Regulatory Summit published a 100-page white paper this week setting out a framework for harmonizing cannabis regulation across different countries and jurisdictions. The document identifies fragmented global regulations as a major barrier to both patient access and international trade, and proposes a working architecture for cross-border alignment — noting that while a legal framework for medical cannabis has existed internationally for more than 60 years, coherent regulatory standards have never followed.
Mary Jane’s Take: Anyone who has followed international cannabis trade knows how significant this problem is. A product that meets the highest safety and quality standards in Canada — EU-GMP certified, independently tested, properly labelled — still faces wildly different import rules, documentation requirements, and scheduling classifications depending on which country it is going to. That inconsistency raises costs, slows access for patients, and creates compliance risk for producers. A serious international framework for regulatory alignment would be genuinely valuable. Whether this white paper gains traction with the governments that need to act on it is the real question — but having a documented blueprint is the necessary first step.
T
hat’s your week — two from the United States, one from the UK, one global. See you next Monday.
— Mary Jane
